Embryotoxicity of Norlestrin, a combined synthetic oral contraceptive, in rhesus macaques (Macaca mulatta)
- 1 April 1983
- journal article
- research article
- Published by Wiley in Teratology
- Vol. 27 (2) , 215-222
- https://doi.org/10.1002/tera.1420270209
Abstract
Thirty timed‐mated pregnant rhesus monkeys received Norlestrin (Norethindrone acetate, 2.5 mg, and ethinyl estradiol, 0.05 mg pertablet, Parke‐Davis) orally at four different dose levels. The dose levels were 5, 10, 25 and 50 mg/day/monkey and the doses were administered during early (days 21–35), late (days 33–46), and throughout (days 21–46) organogenesis, except for the 50‐mg‐dose‐group animals, which were treated only during early organogenesis (days 21–35). All except the animals in the 50‐mg‐dose group were allowed to go to term (165 days gestation). Pregnancy for the animals in the 50‐mg‐dose group was terminated by eesarean section on day 50 of gestation and the fetuses were fixed, serially sectioned, and examined histologically. No teratogenicity was observed. However, the prenatal mortality rate (38.5%) was higher for the Norlestrin‐treated animals than in the control colony (21%). Eight animals aborted between days 40 and 78 of gestation and two other cases resulted in stillbirths at 139 and 165 days of gestation. There was a higher incidence of abortion (44.4%) in the 25‐mg‐dose group. Norlestrin treatment during early organogenesis also resulted in a higher abortion rate (37.5%) compared to treatment during late organogenesis (22.2% abortions). No morphological abnormalities were found in infants observed at birth or in juvenile monkeys which died of natural causes or in those that were sacrificed over a period of two years. No histopathology was observed in the 50‐day‐old fetuses examined by serial section. Examination of endogenous maternal serum estrogen and progesterone levels in Norlestrin‐treated monkeys (25 mg/day, days 21–35) suggested that placental steroidogenesis was not affected; however, the lower levels of estrogen in maternal serum suggested that the ovarian steroidogenesis was affected. Although the precise pathogenesis of this selective embryolethality is not known, several observations in this study suggest a direct generalized embryotoxic effect. Thus, this study for the first time has demonstrated that, while Norlestrin may be embryolethal at 100 times the human contraceptive dose equivalent (25 mg/day) in the rhesus monkey, nevertheless it does not affect the offspring which survive the exposure.This publication has 42 references indexed in Scilit:
- Exogenous progestogen and estrogen implicated in birth defectsJAMA, 1978
- Prenatal toxicity of medroxyprogesterone acetate in rabbits, rats, and miceTeratology, 1977
- Cardiovascular Birth Defects and Antenatal Exposure to Female Sex HormonesNew England Journal of Medicine, 1977
- CONGENITAL ABNORMALITIES AND FIRST-TRIMESTER EXPOSURE TO PROGESTAGEN/ŒSTROGENThe Lancet, 1976
- Normal development of early human embryos: Observation of 90 specimens at Carnegie stages 7 to 13Teratology, 1974
- HORMONE TREATMENT DURING PREGNANCY AND CONGENITAL HEART DEFECTSThe Lancet, 1973
- Hormonal Pregnancy Tests and Neural Tube MalformationsNature, 1971
- Teratogenic and other effects produced in mice by norethynodrel and its 3-hydroxymetabolitesTeratology, 1970
- The Effect of Mestranol on Canine ReproductionBiology of Reproduction, 1969
- Hormonal Pregnancy Tests and Congenital MalformationNature, 1967